Comparison of serum 25-hydroxy vitamin D amongst black African prostate cancer patients with non-aggressive versus aggressive disease using the Gleason score

Julius O. Akhaine; Venyir M. Ramyil; Nuhu K. Dakum; Christian O. Isichei; Samaila I. Shuaibu; Chimaobi G. Ofoha

doi:10.18203/2349-2902.isj20232977

Authors

Julius O. Akhaine Department of Surgery, Jos University Teaching Hospital, Jos, Nigeria
Venyir M. Ramyil Department of Surgery, Jos University Teaching Hospital, Jos, Nigeria
Nuhu K. Dakum Department of Surgery, Jos University Teaching Hospital, Jos, Nigeria
Christian O. Isichei Department of Chemical Pathology, Jos University Teaching Hospital, Jos, Nigeria
Samaila I. Shuaibu Department of Surgery, Jos University Teaching Hospital, Jos, Nigeria
Chimaobi G. Ofoha Department of Surgery, Jos University Teaching Hospital, Jos, Nigeria

DOI:

https://doi.org/10.18203/2349-2902.isj20232977

Keywords:

Serum 25-hydroxy vitamin D, Prostate cancer, Gleason score

Abstract

Background: Black men of African descent have higher risk for developing prostate cancer and present at a younger age with advanced disease and a poorer prognosis. Limited number of studies directly linking serum vitamin D with either prostate cancer prognosis or measures of prostate cancer aggressiveness have been done. The objective of this study is to compare serum 25 hydroxy vitamin D levels in patients with non-aggressive and aggressive prostate cancer using the Gleason score in black Africans in Jos.

Methods: A cross sectional study conducted among fifty patients who presented to the urological surgical out-patient clinic of the Jos University Teaching Hospital who had clinical diagnosis of prostate cancer and were scheduled for prostate biopsy. Blood samples for serum 25-hydroxy vitamin D assay was analysed using the enzyme linked immunosorbent assay (ELISA) technique, patients with histologically confirmed prostate cancer were analysed. Data was collected in a proforma, statistical analysis done using statistical package for the social sciences (SPSS)^(R) version 23 and t-test was used for comparison with a p value <0.05 considered significant.

Results: Fifty patients were studied whose age ranged from 50-89 years. The mean level of serum 25-hydroxy vitamin D was 37.90 ng/ml±17.92. The mean serum 25-hydroxy vitamin D of patients with non-aggressive disease (GS≤6) and aggressive disease (GS≥7) was 48.44±17.09 and 34.57±17.08 respectively with a p value of 0.018.

Conclusions: This study showed that black African prostate cancer patients with high grade tumors (Gleason score ≥7) had significantly lower 25-hydroxy vitamin D levels compared to those with low grade tumors (Gleason score <7).

Metrics

Metrics Loading ...

References

Adeloye D, David RA, Aderemi AV, Iseolorunkanmi A, Oyedokun A, Iweala EE, et al. An Estimate of the Incidence of Prostate Cancer in Africa: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(4):e0153496.

Stephenson AJ, Klein EA. Epidemiology, Etiology, and Prevention of Prostate cancer. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 11th ed. Philadelphia: Elsevier. 2016;2543-64.

Nelson SM, Batai K, Ahaghotu C, Agurs-Collins T, Kittles RA. Association between Serum 25-Hydroxy-Vitamin D and Aggressive Prostate Cancer in African American Men. Nutrients. 2016;9(1):12.

Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, et al. Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer. 2012;131:1187-96.

Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, Bauer DC, et al. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes and Control. 2010;21.

Osegbe DN. Prostate cancer in Nigerians: Facts and nonfacts. J Urolo. 1997;157:13403.

Badmus TA, Adesunkanmi ARK, Yusuf BM, Oseni GO, Eziyi AK, Bakare TIB, et al. Burden of prostate cancer in southwestern nigeria. Urology. 2010;76(2):412-6.

Nwofor AME, Oranusi CK. cancer of the prostate, Nnewi experience. Medical and Dental Consultants’ Association of Nigeria (MDCAN). 2004;65-8.

Ibrahim AG, Aliyu S, Dogo HM, Babayo UD, Zarami AB. Carcinoma of the Prostate - A Five Year Experience in Maiduguri North Eastern Nigeria. Int J Appl Res. 2015;1(8):512-4.

Wang WL, Tenniswood M. Vitamin D, intermediary metabolism and prostate cancer tumor progression. Front Physiol. 2014;5:183.

Gupta D, Vashi PG, Trukova K, Lis CG, Lammersfeld CA. Prevalence of serum vitamin D deficiency and insufficiency in cancer: Review of the epidemiological literature. Exp Therap Med. 2011;2:181-93.

Yaturu S, Zdunek S, Youngberg B. Vitamin D Levels in Subjects with Prostate Cancer Compared to Age-Matched Controls. Prostate Cancer. 2012;1-4.

Nnabugwu II, Udeh EI, Ugwumba FO, Ozoemena FO. Predicting Gleason score using the initial serum total prostate-specific antigen in Black men with symptomatic prostate adenocarcinoma in Nigeria. Clin Intervent Aging. 2016;11:961-6.

Galunska B, Gerova D, Kosev P, Anakievski D. Serum 25-hydroxy vitamin D levels in Bulgarian patients with prostate cancer_ a pilot study. Clin lab. 2015;61(3):329-35.

Murphy AB, Nyame Y, Martin IK, Catalona WJ, Hollowell CMP, Nadler RB, et al. Vitamin D deficiency predicts prostate biopsy outcomes. Clin Cancer Res. 2014;20(9):2289-99.

Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst. 2012;104:690-9.